Neupogen (Filgrastim)

Filgrastim, the active ingredient in Neupogen, is a Granulocyte colony-stimulating factor presented as an injection solution for intravenous or subcutaneous use. It treats neutropenia associated with chemotherapy, bone‑marrow transplantation, severe chronic neutropenia, and aids stem‑cell mobilization.

GNH USA supplies Neupogen as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Neupogen (filgrastim) acts on the granulocyte colony‑stimulating factor pathway to support neutrophil recovery in several clinical settings.

- Chemotherapy‑induced neutropenia: reduces the duration of neutropenia and helps maintain chemotherapy dose intensity. - Neutropenia associated with bone marrow transplantation: supports neutrophil recovery after transplant. - Severe chronic neutropenia: increases neutrophil counts in patients with persistent low levels. - Peripheral blood stem cell mobilization: enhances collection of stem cells for autologous transplantation.

Filgrastim may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Bone pain: mild to moderate discomfort, often in the limbs or back, typically occurring within days of dosing. - Injection site reactions: redness, swelling, itching, or mild bruising at the subcutaneous or intravenous administration site. - Fever: transient elevation of body temperature, occasionally accompanied by chills.

Serious or Rare Side Effects: - Splenic rupture: rare but potentially life‑threatening abdominal event that may present with left‑upper‑quadrant pain and hypotension. - Acute respiratory distress syndrome (ARDS): severe breathing difficulty with rapid onset of hypoxemia and pulmonary infiltrates. - Allergic reactions: anaphylaxis, urticaria, or angioedema that require immediate medical attention.

When using Neupogen, clinicians should consider several safety measures.

- Dose adjustment: modify dose in patients with renal or hepatic impairment based on clinical response. - Monitoring: regularly assess complete blood count to guide therapy duration. - Splenic size: avoid use in patients with known splenomegaly or prior splenic injury. - Concomitant chemotherapy: coordinate timing to prevent overlapping toxicities. - Pregnancy and lactation: use only if potential benefit justifies potential risk, as safety data are limited. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Filgrastim can interact with other agents that affect hematopoiesis or infection risk.

Major Interactions (Avoid): - Concurrent use with other colony‑stimulating factors: may cause excessive leukocytosis. - High‑dose corticosteroids: can blunt the neutrophil response to filgrastim.

Moderate Interactions (Monitor Closely): - Chemotherapy agents: timing should be coordinated to avoid overlapping toxicity. - Antimicrobial agents (e.g., quinolones): may mask infection signs while neutrophil counts rise. - Immunosuppressants (e.g., cyclosporine): monitor for altered neutrophil recovery.